ACE Inhibition and Novel Cardiovascular Risk Factors (TRAIN)
Long Name: ACE Inhibition and Novel Cardiovascular Risk Factors (TRAIN)TRAIN is a double-blind cross-over randomized placebo controlled trial in 294 persons with high cardiovascular risk to assess the effects of 6 month treatment with fosinopril and 6 months with placebo on several markers of fibrinolysis, inflammation, endothelial function and extracellular matrix remodeling. The effects of several genetic polymorphisms were studied on these biomarkers, and test the interaction of the gene polymorphisms with the effects of fosinopril. The assessment of these biological mechanisms will have clinical relevance for identifying the patients who may benefit the most from ACE inhibition. All follow up visits have been completed and data analysis is under way.